Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Non-Hodgkin Lymphoma | Research

The epidemiology of haematological cancers in Sarawak, Malaysia (1996 to 2015)

Authors: Jew Win Kuan, Anselm Ting Su, Mastulu Wahab, Abdullah Hamdan, Jamilah Hashim, Andrew Kiyu, Choo Huck Ooi

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Published epidemiological studies of haematological cancers are few. Hereby we present a 20-year epidemiological data of haematological cancers in Sarawak from a population-based cancer registry.

Methods

Haematological cancer cases with ICD-10 coded C81-C96 and ICD-O coded /3 diagnosed from 1996 to 2015 were retrieved from Sarawak Cancer Registry. Adult was defined as those 15 years and above. Incidence rate (IR) was calculated based on yearly Sarawak citizen population stratified to age, gender, and ethnic groups. Age-standardised IR (ASR) was calculated using Segi World Standard Population.

Results

A total of 3,947 cases were retrieved and analysed. ASR was 10 and male predominance (IR ratio 1.32, 95%CI 1.24,1.41). Haematological cancers generally had a U-shaped distribution with lowest IR at age 10–14 years and exponential increment from age 40 years onwards, except acute lymphoblastic leukaemia (ALL) with highest IR in paediatric 2.8 versus adult 0.5. There was a significant difference in ethnic and specific categories of haematological cancers, of which, in general, Bidayuh (IR ratio 1.13, 95%CI 1.00, 1.27) and Melanau (IR ratio 0.54, 95%CI 0.45, 0.65) had the highest and lowest ethnic-specific IR, respectively, in comparison to Malay. The ASR (non-Hodgkin lymphoma, acute myeloid leukaemia, ALL, chronic myeloid leukaemia, and plasma cell neoplasm) showed a decreasing trend over the 20 years, -2.09 in general, while Hodgkin lymphoma showed an increasing trend of + 2.80. There was crude rate difference between the 11 administrative divisions of Sarawak.

Conclusions

This study provided the IR and ASR of haematological cancers in Sarawak for comparison to other regions of the world. Ethnic diversity in Sarawak resulted in significant differences in IR and ASR.
Appendix
Available only for authorised users
Literature
4.
go back to reference Ooi CH, Yao SK, Usop AKD, Bakar H, Wahab M, Assan J. Epidemiology of Cancer in Sarawak 1996 to 2000. Sarawak: Sarawak Health Department; 2005. Ooi CH, Yao SK, Usop AKD, Bakar H, Wahab M, Assan J. Epidemiology of Cancer in Sarawak 1996 to 2000. Sarawak: Sarawak Health Department; 2005.
5.
go back to reference Ooi CH, Wahab M. Epidemiology of Cancer in Sarawak 2001–2005. Sarawak: Sarawak Health Department; 2009. Ooi CH, Wahab M. Epidemiology of Cancer in Sarawak 2001–2005. Sarawak: Sarawak Health Department; 2009.
6.
go back to reference Segi M. Cancer mortality for selected sites in 24 countries. Nagoya, Japan: Japan Cancer Society; 1950. Segi M. Cancer mortality for selected sites in 24 countries. Nagoya, Japan: Japan Cancer Society; 1950.
8.
go back to reference Chang YM, Swaran Y, Phoon YK, Sothirasan K, Sim HT, Lim KB, et al. Haplotype diversity of 17 Y-chromosomal STRs in three native Sarawak populations (Iban, Bidayuh and Melanau) in East Malaysia. Forensic Sci Int Genet. 2009;3(3):e77-80.CrossRefPubMed Chang YM, Swaran Y, Phoon YK, Sothirasan K, Sim HT, Lim KB, et al. Haplotype diversity of 17 Y-chromosomal STRs in three native Sarawak populations (Iban, Bidayuh and Melanau) in East Malaysia. Forensic Sci Int Genet. 2009;3(3):e77-80.CrossRefPubMed
9.
go back to reference Linton RE, Daker M, Khoo AS, Choo DCY, Viljoen M, Neilsen PM. Nasopharyngeal carcinoma among the Bidayuh of Sarawak, Malaysia: History and risk factors. Oncol Lett. 2021;22(1):514.CrossRefPubMedPubMedCentral Linton RE, Daker M, Khoo AS, Choo DCY, Viljoen M, Neilsen PM. Nasopharyngeal carcinoma among the Bidayuh of Sarawak, Malaysia: History and risk factors. Oncol Lett. 2021;22(1):514.CrossRefPubMedPubMedCentral
10.
go back to reference Devi BC, Pisani P, Tang TS, Parkin DM. High incidence of nasopharyngeal carcinoma in native people of Sarawak Borneo Island. Cancer Epidemiol Biomarkers Prev. 2004;13(3):482–6.CrossRefPubMed Devi BC, Pisani P, Tang TS, Parkin DM. High incidence of nasopharyngeal carcinoma in native people of Sarawak Borneo Island. Cancer Epidemiol Biomarkers Prev. 2004;13(3):482–6.CrossRefPubMed
12.
go back to reference Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14.CrossRefPubMedPubMedCentral Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14.CrossRefPubMedPubMedCentral
13.
go back to reference Park W-J, Park J-H, Cho S, Shin MG. Twenty-year incidence trend of hematologic malignancies in the Republic of Korea: 1999–2018. Blood Res. 2021;56(4):301–14.CrossRefPubMedPubMedCentral Park W-J, Park J-H, Cho S, Shin MG. Twenty-year incidence trend of hematologic malignancies in the Republic of Korea: 1999–2018. Blood Res. 2021;56(4):301–14.CrossRefPubMedPubMedCentral
14.
go back to reference Solans M, Fàbrega A, Morea D, Auñon-Sanz C, Granada I, Roncero JM, et al. Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province Spain. Cancer Epidemiol. 2019;58:8–11.CrossRefPubMed Solans M, Fàbrega A, Morea D, Auñon-Sanz C, Granada I, Roncero JM, et al. Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province Spain. Cancer Epidemiol. 2019;58:8–11.CrossRefPubMed
15.
go back to reference Kuan JW, Melaine MS. The epidemiology of chronic myeloid leukaemia in southern Sarawak Borneo Island. Med J Malaysia. 2018;73(2):78–85.PubMed Kuan JW, Melaine MS. The epidemiology of chronic myeloid leukaemia in southern Sarawak Borneo Island. Med J Malaysia. 2018;73(2):78–85.PubMed
16.
go back to reference Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–7.CrossRefPubMedPubMedCentral Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–7.CrossRefPubMedPubMedCentral
17.
go back to reference Miranda-Filho A, Piñeros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control. 2019;30(5):489–99.CrossRefPubMed Miranda-Filho A, Piñeros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control. 2019;30(5):489–99.CrossRefPubMed
18.
go back to reference Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48.CrossRefPubMedPubMedCentral Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48.CrossRefPubMedPubMedCentral
19.
go back to reference Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19.CrossRefPubMedPubMedCentral Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19.CrossRefPubMedPubMedCentral
Metadata
Title
The epidemiology of haematological cancers in Sarawak, Malaysia (1996 to 2015)
Authors
Jew Win Kuan
Anselm Ting Su
Mastulu Wahab
Abdullah Hamdan
Jamilah Hashim
Andrew Kiyu
Choo Huck Ooi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10988-y

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine